Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...
Leveraging profound knowledge in radiopharmaceutical drug development and commercial planning, Dr. Meyrick will lead the medical team in further developing and delivering on ITM's pipeline...
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and M¼nster, April 23, 2024 “ The Departments of Neurosurgery and Nuclear Medicine at the University...